Skip Navigation

Severe Weather Alert - Updated: 11:30 am, January 17, 2018

Due to rapidly changing weather conditions, all Wake Forest Baptist Health clinics will be closing today (January 17, 2018) at 2 pm, and will reopen tomorrow (January 18, 2018) by 10 am. 
Urgent Care – Clemmons and Urgent Care – Mocksville will be closing today (January 17) at 4 pm, and will reopen tomorrow (January 18) by 10 am.
If you have questions, please contact the clinic directly.

Jill Elaine Wykosky, PhD

wykosky

Staff Scientist
Takeda Pharmaceutical
Greater San Diego Area, CA 

Email:jwykosky@ucsd.edu

Education:

Ph.D., Molecular Medicine and Translational Science Graduate Program, May 2008
Wake Forest University Graduate School of Arts and Sciences

 

Areas of specialization: Cancer Biology, Brain Tumor Biology

B.S., Microbiology with Honors in Biological Sciences, 1999-2003, Summa cum Laude
Related area, Chemistry
University of Pittsburgh, Pittsburgh, Pennsylvania,

Certified, Conceptual Foundations of Medicine

Research Interests:

The oncogenic role of signal transduction mediated by protein or lipid phosphatases as well as the differences between the signaling effected by oncogenic mutant receptors and their normal wild-type counterparts.

Publications:

Wykosky J and Debinski W. Molecular Targeting of IL-13R2 and EphA2 Receptor in GBM. In: E.G. Van Meir (Ed.) CNS Cancer: Models, Prognostic Factors, and Targets. Dec 2008. Springer.

Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, and Debinski W. Soluble, monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene, advance online publication, 15 September 2008.

Wykosky J and Debinski W. Function and therapeutic targeting of the EphA2/ephrinA1 system in solid tumors. Molecular Cancer Research, 2008, In press.

Wykosky J, Gibo DM, Stanton C, and Debinski W. IL-13 Receptor alpha 2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas. Clinical Cancer Research 14(1), 199-208, 2008.

Wykosky J, Gibo DM, and Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. MolecularCancer Therapeutics 6(12): 3208-3218, 2007.

For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine.

Grants:

NRSA Pre-doctoral fellowship: NINDS, 2006-2008
F31 NSO55533-01 “EphA2: Function and Targeting in Malignant Gliomas”

Quick Reference

Contact Information
Molecular Medicine and Translational Science Graduate Program

Office 336-713-4259

Kay Collare

336-713-4259

kcollare@wakehealth.edu

Find A Doctor Ways to Give
Last Updated: 07-11-2016
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.